Multiresistant bacterial pathogens such as methicillin-resistant Staphylococcus aureus, multiresistant Streptococcus pneumoniae, vancomycin-resistant enterococci and multiresistant Pseudomonas aeruginosa are being seen with increasing frequency in the community and not just in hospital practice. Treatment options for infections caused by these pathogens are limited, but in most cases a suitable drug can be found. In particular, there are options for the treatment of the community-associated strains of MrSA, such as trimethoprim-sulfamethoxazole, and often macrolides or lincosamides.
Introduction
General practitioners are often faced with patients suffering from infections caused by bacteria harbouring some kind of antibiotic resistance. Many of these resistances are so common that we take them for granted -for example, penicillin resistance in Staphylococcus aureus occurs in about 90% of community strains, and amoxycillin resistance in about 50%
of Escherichia coli. Usually there are options for antibiotic treatment (see Table 1 ), and laboratories attempt to provide susceptibility data. However, for some resistant organisms the options are limited, problematic or both. The generic term for these strains is multiresistant organisms.
Methicillin-resistant Staphylococcus aureus (MrSA)
Even though methicillin itself is no longer used, the term methicillin-resistant is still used to identify these very important multiresistant organisms. The general practitioner is likely to encounter two types of MRSA. These are the multiresistant MRSA strains that are hospital-associated which are found colonising or occasionally infecting patients who have previously been hospitalised, and the non-multiresistant community-associated MRSA strains which are found in all those common circumstances where one would expect to see susceptible S. aureus, namely boils, furuncles, cellulitis and wound infections. Purulent forms of staphylococcal skin infection respond best to drainage, and for small lesions drainage without antibacterial treatment will be usually adequate. 1 When antibacterial treatment is required for MRSA infection, 
Multiresistant Streptococcus pneumoniae
Before the introduction of a conjugate pneumococcal vaccine into the childhood immunisation schedule, the proportion of multiresistant S. pneumoniae strains in the community was increasing. They are less prevalent now, in part due to the overall decrease in pneumococcal infections as a result of the conjugate vaccine, but they will still be encountered. 
Colonisation
There are no effective treatments for the colonised state.
Furthermore, if the isolate is from the urine of a patient with an indwelling catheter without any systemic symptoms, this represents colonisation rather than true infection and treatment is not warranted.
Multiresistant Escherichia coli
over 5% of clinical E. coli isolates in Australia are resistant to more than three antibacterial drugs recommended for use -resistance to amoxycillin, cefazolin/cephalexin and trimethoprim/sulfamethoxazole is the commonest profile. 4 Reduced susceptibility or resistance to amoxycillin-clavulanate is also found in more than 8% of all E. coli and in up to 13% of Multiresistant strains may be encountered in the community, most commonly in complicated urinary tract infection.
Treatment of mild to moderate urinary infection caused by these strains will be defined by the results of susceptibility tests. If the isolate is susceptible to ciprofloxacin, this drug can be given orally to outpatients. otherwise, all other drugs must be administered parenterally, and hospital management is usually required. Strains isolated from otitis externa will usually respond adequately to topical treatment.
Conclusion
Although there are limited treatment options for infections caused by multiresistant organisms, there are still drugs available in the community in many cases and hospitalisation for more complex parenteral therapy can be avoided.
In general, treatment of colonisation with multiresistant organisms is not required. 
